Exchange: NASDAQ·Updated 04:00 PM EST

STLN Earnings

Latest Earnings Results: Q3 '26

Reported: Nov 05

Estimated EPS

-$0.05

Reported EPS

-$0.13

Surprise

-160%

Estimated Rev

$168.68M

Reported Rev

$169.77M

Surprise

+0.65%

Starling Oncology's FY2026 updated guidance is revenue of $650M, gross profit of $107M, Adjusted EBITDA of $4M, and Free Cash Flow of $5M.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$0.04
--
--
N/A
Q3 '26
-$0.05
-$0.13
-160.00%
MISSED
Q2 '26
-$0.06
-$0.08
-25.00%
MISSED
Q1 '26
--
-$0.02
--
N/A

Advertisement|Remove ads.